{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"76.9","value":"3370"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.9","value":"3570"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.4","value":"3400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Predose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"description":"A predose PK sample was considered dose-compliant based on the following criteria: A participant must have received 21 consecutive days of 1 mg talazoparib without dosing interruption prior to sample collection; and the predose PK sample must have been collected 24 hours +/- 10 percent (2 hours and 24 minutes) after the previous day's dose and no more than 5 minutes (0.083 hours) after the administration of the dose on the day of PK sample collection.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or sponsor's decision to terminate the trial (up to a maximum of 70.2 months). One cycle was of 21 days.","id":"OG000","title":"Talazoparib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis population included participants who received at least 1 dose of talazoparib and had dose compliant pharmacokinetic (PK) predose sample. Here, \"number analyzed\" signifies number of participants who were evaluable for the specified categories. This endpoint was not planned to be analyzed for the reporting arm \"Physician's Choice Treatment\".","reportingStatus":"POSTED","timeFrame":"Predose on Day 1 of Cycle 2, 3 and 4","title":"Trough Plasma Talazoparib Concentrations","type":"SECONDARY","unitOfMeasure":"Picogram per milliliter (pg/mL)"}